Company Presentation
Coiled Therapeutics plc has announced that its investor presentation for the Proactive One2One Investor Forum is available for download on their website, ahead of their presentation today. The company, an AIM-listed clinical-stage oncology firm developing precision medicines, is focused on its lead program AO-252, a TACC3 inhibitor currently in Phase I clinical trials in the USA for hard-to-treat cancers, with plans to initiate dose-expansion cohorts in prostate and ovarian cancer during 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your COIL notes
Coiled Therapeutics (AIM: COIL) (OTCQB: COTFX), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that ahead of its presentation at the Proactive One2One Investor Forum in London at 6pm BST today, the presentation is available to download from the Coiled Therapeutics website at https://coiledplc.com/investors/results-reports.
The Forum will be hosted at The Chesterfield Mayfair, 35 Charles Street, London, W1J 5EB.
In order to register for the event, please use the following link:
About AO-252
For more information, please visit: www.coiledplc.com and follow us on LinkedIn.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.